Cargando…
Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients
BACKGROUND: Taurolidin/Citrate (TauroLock™), a lock solution with broad spectrum antimicrobial activity, may prevent bloodstream infection (BSI) due to coagulase-negative staphylococci (CoNS or 'MRSE' in case of methicillin-resistant isolates) in pediatric cancer patients with a long term...
Autores principales: | Simon, Arne, Ammann, Roland A, Wiszniewsky, Gertrud, Bode, Udo, Fleischhack, Gudrun, Besuden, Mette M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515312/ https://www.ncbi.nlm.nih.gov/pubmed/18664278 http://dx.doi.org/10.1186/1471-2334-8-102 |
Ejemplares similares
-
Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients
por: Reidenberg, Bruce E., et al.
Publicado: (2017) -
Taurolidine Lock Is Superior to Heparin Lock in the Prevention of Catheter Related Bloodstream Infections and Occlusions
por: Olthof, Evelyn D., et al.
Publicado: (2014) -
The European TauroPace™ Registry
por: Vonthein, Reinhard, et al.
Publicado: (2023) -
Is Taurolidine-citrate an effective and cost-effective hemodialysis catheter lock solution? A systematic review and cost- effectiveness analysis
por: Kavosi, Zahra, et al.
Publicado: (2016) -
The best solution down the line: an observational study on taurolidine- versus citrate-based lock solutions for central venous catheters in hemodialysis patients
por: van Roeden, Sonja, et al.
Publicado: (2021)